Victoria Socha

DocwireNews

Approximately 20% to 25% of hospital admissions are complicated by acute kidney injury (AKI) events. AKI-related events are associated with increased rates of long-term mortality. Effective blood pressure control following AKI may have beneficial effects on outcomes, but there are few data available on appropriate blood pressure targets and the optimal timing of initiation of blood pressure-lowering medication.Benjamin R. Griffin and colleagues at the University of Iowa Hospital &amp; Clinics, Iowa City, conducted a retrospective cohort analysis of data on US veterans with in-hospital AKI. Results of the analysis were reported during a poster session at the American Society of Nephrology Kidney Week 2023. The poster was titled Time to Blood Pressure Control and Blood Pressure Targets Significantly Impact Mortality Among Veterans Following AKI.The cohort included veterans admitted to the hospital from 2013 to 2018 who experienced an in-hospital AKI event. Eligible patients had one or more blood pressure measurement within 30 days of hospital discharge. Systolic blood pressure was treated as time dependent and categorized as &lt;120, 120-129, and 130-139 mm Hg, relative to &gt;140 mm Hg.The primary outcome of interest was time to death. Cox proportional hazards regression models were adjusted for demographics, chronic lung disease, unexplained weight loss, dementia, congestive heart failure, hematocrit, blood urea nitrogen, bilirubin, and albumin. Hazard ratios (HRs) were calculated at seven different time points to evaluate the impact of blood pressure control over time (30, 60, 120, 180, 270, and 365 days after discharge).The cohort included 97,376 veterans. Of those, 15% (n=14,819) died within 1 year of hospital discharge. Rates of hypertension, congestive heart failure, and diabetes were high in the overall cohort (85%, 28%, and 19%, respectively). Relative to uncontrolled blood pressure, HRs for mortality were significantly reduced for all blood pressure categories &lt;140 mm Hg. The lowest HRs were in the group with blood pressure 130-139 mm Hg. Relative to uncontrolled blood pressure, HRs were lowest at the 30-day mark for all blood pressure categories and increased over time.In summary, the authors said, &ldquo;Among post-AKI veterans, blood pressure control within 30 days of discharge was associated with reduced mortality, but this benefit was attenuated over time. All blood pressure targets were superior to blood pressure &gt;140 mm Hg, but the 130-139 mm Hg group had the lowest risk of death at each time point. These findings highlight the importance of achieving blood pressure control promptly post-AKI and suggest that targeting a systolic blood pressure of 130-139 is ideal.&rdquo;Source: Griffin BR, Sarrazin MV, Masaaki Y, et al. Time to blood pressure control and blood pressure targets significantly impact mortality among veterans following AKI. FR-PO105. Abstract of a poster presented at the American Society of Nephrology Kidney Week 2023; November 3, 2023; Philadelphia, Pennsylvania.

MarkAlain Déry, DO

Eric Griggs, MD

Measles in America: An Ongoing Problem

Infectious Disease

Roger Rodby, MD

Joel M. Topf, MD, FACP

Seldin Award Winner Advocates Online Education

NKF Spring Clinical Meetings 2025

Hatem Soliman, MD

The Future of Dendritic Cell Vaccines in HER2+ Breast Cancer: Toward De-Escalation of Chemotherapy

HER2 Breast Cancer

Latest News

Blood Pressure Control and Mortality After AKI

ASN Kidney Week 2023

Relative to uncontrolled blood pressure, HRs for mortality were significantly reduced for all blood pressure categories <140 mm Hg.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe